Once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes in China: A cost-utility and budget impact analysis.

AIMS: Insulin icodec, the first once-weekly basal insulin analogue, was approved in China in 2024. Although it has demonstrated robust clinical efficacy, its budget impact remains unknown, and the long-term cost-utility within the reimbursement conte…

Preview only. Read the full abstract at the source